ClinicalTrials.gg
CompletedNCT06172348Updated Apr 10, 2025Results posted

A Study to Learn About Three Forms of The Study Medicine (Ritlecitinib) in Healthy Adults

A Phase 1 interventional study of Ritlecitinib in Healthy Volunteers, sponsored by Pfizer. Completed at 1 site in Belgium. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-10.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to compare if three forms of study medicine (called ritlecitinib) get processed differently in healthy adults.

This study is seeking healthy participants who have:

  • Aged 18 years or older;
  • male or female who are healthy as determined by medical assessment;
  • BMI of 16-32 kg/m2, and a total body weight >45 kg (99 lb).

All participants in this study will receive a ritlecitinib oral dose in three different forms (solution, capsule 1 and capsule 2).

The study will take up to 2.5 months, including the screening period and follow-up phone call. Participants will have to stay at the study clinic for at least 13 days. There will be 4 periods in total for this study. On day 1 of each period, participants will take one form of Riltecitinib without food for the first three periods and with food for the last period. Participants will have blood samples taken both before and after taking ritlecitinib. A follow-up phone call will be made at 28 to 35 days after the last study period.

Read the detailed description

Ritlecitinib is a covalent and irreversible inhibitor of JAK3 with high selectivity over the other JAK isoforms (JAK1, JAK2, and TYK2). Ritlecitinib also inhibits irreversibly the TEC family kinases with selectivity over the broader human kinome. Treatment with ritlecitinib is expected to inhibit the inflammatory pathways mediated by IL 7, IL 15 and IL 21, all implicated in UC, CD, AA, RA, and vitiligo and therefore under development in these indications. Moreover, due to lack of activity against the other JAK isoforms, ritlecitinib is expected to spare immunoregulatory cytokines such as IL 10, IL 27 and IL 35, which are critical to the maintenance of immunosuppressive functions and immune homeostasis.

This study aims to investigate the pharmacokinetics (PK) and relative bioavailability of 2 new modified release (MR) capsule formulations of ritlecitinib, MR1 (release duration: 6-8 hours) and MR2 (release duration:13 15 hours) as single doses in fasted and fed conditions.

This is a single dose, open-label, randomized, 4-period, 6-sequence crossover study in a single cohort of approximately 12 healthy participants randomized to one of the sequences (containing 1 solution and 2 modified release [MR1 and MR2] capsule formulations of ritlecitinib) described in the table below. The first 3 periods are under fasted condition and the fourth period is under fed condition to investigate the effect of food on the PK of MR1 and MR2.

For a given participant, the total study duration from screening to follow-up phone call will be between approximately 8 to 11 weeks.

Screening will occur within 28 days prior to the first dose of the study intervention. Each participant will go through Periods 1 through 4 and dosing in each treatment period will be separated by at least 3 days to minimize any carryover effect.

Venous PK blood samples for PK analysis will be collected pre-dose and post-dose in each period.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Pharmacokinetics
  • Adults
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female participants aged 18 years or older (or the minimum age of consent in accordance with local regulations) at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, and laboratory tests.
  2. of 16-32 kg/m2, and a total body weight >45 kg (99 lb).
  3. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  4. Capable of giving signed

Exclusion criteria

Exclusion Criteria:

  1. Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  2. Participants with the acute or chronic infections or infection history
  3. History of febrile illness within 5 days prior to the first dose of study intervention.
  4. History of any lymphoproliferative disorder such as EBV related lymphoproliferative disorder, history of lymphoma, history of leukemia, or signs or symptoms suggestive of current lymphatic or lymphoid disease.
  5. Known present or a history of other than a successfully treated or excised nonmetastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.
  6. History of active or latent Mycobacterium TBA: participant who is currently being treated for active or latent Mycobacterium TB infection or has a history of Mycobacterium TB must be excluded from the study.
  7. Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality or other conditions that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Treatment Sequence 1

    Ritlecitinib 100 mg solution (fasted, Period 1), followed by ritlecitinib 100 mg MR capsule 1 (fasted, Period 2), followed by ritlecitinib 100 mg MR capsule 2 (fasted, Period 3), and followed by ritlecitinib 100 mg MR capsule 1 (fed, Period 4)

    Drug: Ritlecitinib

  • Experimental
    Treatment Sequence 2

    Ritlecitinib 100 mg MR capsule 1 (fasted, Period 1), followed by ritlecitinib 100 mg MR capsule 2 (fasted, Period 2), followed by ritlecitinib 100 mg solution (fasted, Period 3), and followed by ritlecitinib 100 mg MR capsule 1 (fed, Period 4)

    Drug: Ritlecitinib

  • Experimental
    Treatment Sequence 3

    Ritlecitinib 100 mg MR capsule 2 (fasted, Period 1), followed by ritlecitinib 100 mg solution (fasted, Period 2), followed by ritlecitinib 100 mg MR capsule 1 (fasted, Period 3), and followed by ritlecitinib 100 mg MR capsule 1 (fed, Period 4)

    Drug: Ritlecitinib

  • Experimental
    Treatment Sequence 4

    Ritlecitinib 100 mg solution (fasted, Period 1), followed by ritlecitinib 100 mg MR capsule 1 (fasted, Period 2), followed by ritlecitinib 100 mg MR capsule 2 (fasted, Period 3), and followed by ritlecitinib 100 mg MR capsule 2 (fed, Period 4)

    Drug: Ritlecitinib

  • Experimental
    Treatment Sequence 5

    Ritlecitinib 100 mg MR capsule 1 (fasted, Period 1), followed by ritlecitinib 100 mg MR capsule 2 (fasted, Period 2), followed by ritlecitinib 100 mg solution (fasted, Period 3), and followed by ritlecitinib 100 mg MR capsule 2 (fed, Period 4)

    Drug: Ritlecitinib

  • Experimental
    Treatment Sequence 6

    Ritlecitinib 100 mg MR capsule 2 (fasted, Period 1), followed by ritlecitinib 100 mg solution (fasted, Period 2), followed by ritlecitinib 100 mg MR capsule 1 (fasted, Period 3), and followed by ritlecitinib 100 mg MR capsule 2 (fed, Period 4)

    Drug: Ritlecitinib

Interventions

  • Ritlecitinib 100 milligrams (mg) will be provided as either solution or capsule formulation (2 capsules of 50 mg)

    Also known as: PF-06651600

06

What researchers measure

Primary outcomes

  1. Maximum Observed Concentration (Cmax) of Ritlecitinib: MR Capsules vs Oral Solution Under Fasted Condition

    Time frame: For oral solution: Pre-dose (0 hours), 0.5, 1, 2, 3, 4, 6, 10, 12 and 24 hours post-dose on Day 1 of Period 1, 2 or 3; for MR1 and MR2 capsules: Pre-dose (0 hours), 1, 2, 3, 4, 6, 10, 12,16, 24, 36 and 48 hours post-dose on Day 1 of Period 1, 2 or 3

  2. Area Under the Plasma Concentration-Time Profile From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of Ritlecitinib: MR Capsules vs Oral Solution Under Fasted Condition

    AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

    Time frame: For oral solution: Pre-dose (0 hours), 0.5, 1, 2, 3, 4, 6, 10, 12 and 24 hours post-dose on Day 1 of Period 1, 2 or 3; for MR1 and MR2 capsules: Pre-dose (0 hours), 1, 2, 3, 4, 6, 10, 12,16, 24, 36 and 48 hours post-dose on Day 1 of Period 1, 2 or 3

Secondary outcomes

  1. Cmax of Ritlecitinib: MR Capsules Under Fed vs Fasted Condition

    Time frame: Pre-dose (0 hours), 1, 2, 3, 4, 6, 10, 12,16, 24, 36 and 48 hours post-dose on Day 1 of Period 1, 2, 3 (for fasted) or 4 (for fed)

  2. AUCinf of Ritlecitinib: MR Capsules Under Fed vs Fasted Condition

    AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

    Time frame: Pre-dose (0 hours), 1, 2, 3, 4, 6, 10, 12,16, 24, 36 and 48 hours post-dose on Day 1 of Period 1, 2, 3 (for fasted) or 4 (for fed)

  3. Number of Participants With Adverse Events (AEs)

    An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: From start of study treatment up to 35 days after administration of last dose of study intervention (maximum up to 45 days)

  4. Number of Participants With Clinically Significant Laboratory Test Abnormalities

    Laboratory parameters included: Hematology: lymphocytes/leukocytes, eosinophils/leukocytes greater than (\>) 1.2\*upper limit of normal (ULN) (percent \[%\]), neutrophils/leukocytes less than (\<) 0.8\*lower limit of normal (LLN) (%); Urinalysis: urine hemoglobin, nitrite greater than or equal to (\>=) 1, bacteria \> 20 (per high power field \[/HPF\]). Clinical significance was judged by investigator.

    Time frame: From start of study treatment up to Day 3 of Period 4 (maximum up to Day 12, each Period = 3 days)

  5. Number of Participants With Clinically Significant Vital Signs Abnormalities

    Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate (PR) were measured in a supine position. Criteria for vital signs included: SBP: value less than (\<) 90 millimeter of mercury (mmHg), change greater than or equal to (\>=) 30 mmHg decrease, change \>= 30 mmHg increase; DBP: value \< 50 mmHg, change \>= 20 mmHg decrease, change \>= 20 mmHg increase; PR: value \< 40 beats per minute (bpm), value \> 120 bpm. Clinical significance was judged by investigator.

    Time frame: From start of study treatment up to Day 3 of Period 4 (maximum up to Day 12, each Period = 3 days)

  6. Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities

    Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT, corrected QT (Fridericia method) (QTcF) and QRS intervals. Clinical significance was judged by investigator.

    Time frame: From start of study treatment up to Day 3 of Period 4 (maximum up to Day 12, each Period = 3 days)

07

Results

Posted Apr 10, 2025

Participant flow

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneTreatment Sequence 1: A Then B Then C Then B (Fed)Treatment Sequence 2: B Then C Then A Then B (Fed)Treatment Sequence 3: C Then A Then B Then B (Fed)Treatment Sequence 4: A Then B Then C Then C (Fed)Treatment Sequence 5: B Then C Then A Then C (Fed)Treatment Sequence 6: C Then A Then B Then C (Fed)
Started222222
Completed222222
Not completed000000
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneTreatment Sequence 1: A Then B Then C Then B (Fed)Treatment Sequence 2: B Then C Then A Then B (Fed)Treatment Sequence 3: C Then A Then B Then B (Fed)Treatment Sequence 4: A Then B Then C Then C (Fed)Treatment Sequence 5: B Then C Then A Then C (Fed)Treatment Sequence 6: C Then A Then B Then C (Fed)
Started222222
Completed221222
Not completed001000
Withdrew: Adverse event001000
Treatment Period 3
Participant flow — Treatment Period 3
MilestoneTreatment Sequence 1: A Then B Then C Then B (Fed)Treatment Sequence 2: B Then C Then A Then B (Fed)Treatment Sequence 3: C Then A Then B Then B (Fed)Treatment Sequence 4: A Then B Then C Then C (Fed)Treatment Sequence 5: B Then C Then A Then C (Fed)Treatment Sequence 6: C Then A Then B Then C (Fed)
Started221222
Completed221222
Not completed000000
Treatment Period 4
Participant flow — Treatment Period 4
MilestoneTreatment Sequence 1: A Then B Then C Then B (Fed)Treatment Sequence 2: B Then C Then A Then B (Fed)Treatment Sequence 3: C Then A Then B Then B (Fed)Treatment Sequence 4: A Then B Then C Then C (Fed)Treatment Sequence 5: B Then C Then A Then C (Fed)Treatment Sequence 6: C Then A Then B Then C (Fed)
Started221222
Completed221222
Not completed000000

Outcome measures

PrimaryMaximum Observed Concentration (Cmax) of Ritlecitinib: MR Capsules vs Oral Solution Under Fasted Condition
Time frame:
For oral solution: Pre-dose (0 hours), 0.5, 1, 2, 3, 4, 6, 10, 12 and 24 hours post-dose on Day 1 of Period 1, 2 or 3; for MR1 and MR2 capsules: Pre-dose (0 hours), 1, 2, 3, 4, 6, 10, 12,16, 24, 36 and 48 hours post-dose on Day 1 of Period 1, 2 or 3
Reported as:
Geometric mean · Nanogram per milliliter (ng/mL)
Maximum Observed Concentration (Cmax) of Ritlecitinib: MR Capsules vs Oral Solution Under Fasted Condition
Nanogram per milliliter (ng/mL)Ritlecitinib 100 mg Oral Solution (Fasted)Ritlecitinib 100 mg MR1 Capsule (Fasted)Ritlecitinib 100 mg MR2 Capsule (Fasted)
Maximum Observed Concentration (Cmax) of Ritlecitinib: MR Capsules vs Oral Solution Under Fasted Condition671.6 ± 24145.1 ± 2584.96 ± 25
Statistical analysis
  • Ritlecitinib 100 mg Oral Solution (Fasted) vs Ritlecitinib 100 mg MR1 Capsule (Fasted) · Ratio of adjusted geometric means: 21.89 · 90% CI 19.31 to 24.80Ratios (Test/Reference) and 90 percent (%) confidence intervals were expressed as percentages. Test = MR1 capsule; Reference = Oral solution.
  • Ritlecitinib 100 mg Oral Solution (Fasted) vs Ritlecitinib 100 mg MR2 Capsule (Fasted) · Ratio of adjusted geometric means: 12.65 · 90% CI 11.21 to 14.27Ratios (Test/Reference) and 90% confidence intervals were expressed as percentages. Test = MR2 capsule; Reference = Oral solution.
PrimaryArea Under the Plasma Concentration-Time Profile From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of Ritlecitinib: MR Capsules vs Oral Solution Under Fasted Condition

AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

Time frame:
For oral solution: Pre-dose (0 hours), 0.5, 1, 2, 3, 4, 6, 10, 12 and 24 hours post-dose on Day 1 of Period 1, 2 or 3; for MR1 and MR2 capsules: Pre-dose (0 hours), 1, 2, 3, 4, 6, 10, 12,16, 24, 36 and 48 hours post-dose on Day 1 of Period 1, 2 or 3
Reported as:
Geometric mean · Nanogram*Hour per milliliter (ng*hr/mL)
Area Under the Plasma Concentration-Time Profile From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of Ritlecitinib: MR Capsules vs Oral Solution Under Fasted Condition
Nanogram*Hour per milliliter (ng*hr/mL)Ritlecitinib 100 mg Oral Solution (Fasted)Ritlecitinib 100 mg MR1 Capsule (Fasted)Ritlecitinib 100 mg MR2 Capsule (Fasted)
Area Under the Plasma Concentration-Time Profile From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of Ritlecitinib: MR Capsules vs Oral Solution Under Fasted Condition1261 ± 231067 ± 28970.6 ± 22
Statistical analysis
  • Ritlecitinib 100 mg Oral Solution (Fasted) vs Ritlecitinib 100 mg MR1 Capsule (Fasted) · Ratio of adjusted geometric means: 86.49 · 90% CI 79.11 to 94.54Ratios (Test/Reference) and 90% confidence intervals were expressed as percentages. Test = MR1 capsule; Reference = Oral solution.
  • Ritlecitinib 100 mg Oral Solution (Fasted) vs Ritlecitinib 100 mg MR2 Capsule (Fasted) · Ratio of adjusted geometric means: 76.99 · 90% CI 70.65 to 83.90Ratios (Test/Reference) and 90% confidence intervals were expressed as percentages. Test = MR2 capsule; Reference = Oral solution.
SecondaryCmax of Ritlecitinib: MR Capsules Under Fed vs Fasted Condition
Time frame:
Pre-dose (0 hours), 1, 2, 3, 4, 6, 10, 12,16, 24, 36 and 48 hours post-dose on Day 1 of Period 1, 2, 3 (for fasted) or 4 (for fed)
Reported as:
Geometric mean · Nanogram per milliliter (ng/mL)
Cmax of Ritlecitinib: MR Capsules Under Fed vs Fasted Condition
Nanogram per milliliter (ng/mL)Ritlecitinib 100 mg MR1 Capsule (Fasted)Ritlecitinib 100 mg MR2 Capsule (Fasted)Ritlecitinib 100 mg MR1 Capsule (Fed)Ritlecitinib 100 mg MR2 Capsule (Fed)
Cmax of Ritlecitinib: MR Capsules Under Fed vs Fasted Condition145.1 ± 2584.96 ± 25177.1 ± 16112.0 ± 14
Statistical analysis
  • Ritlecitinib 100 mg MR1 Capsule (Fasted) vs Ritlecitinib 100 mg MR1 Capsule (Fed) · Ratio of adjusted geometric means: 123.92 · 90% CI 105.16 to 146.02Ratios (Test/Reference) and 90% confidence intervals were expressed as percentages. Test = MR1 capsule (fed); Reference = MR1 capsule (fasted).
  • Ritlecitinib 100 mg MR2 Capsule (Fasted) vs Ritlecitinib 100 mg MR2 Capsule (Fed) · Ratio of adjusted geometric means: 129.79 · 90% CI 111.51 to 151.06Ratios (Test/Reference) and 90% confidence intervals were expressed as percentages. Test = MR2 capsule (fed); Reference = MR2 capsule (fasted).
SecondaryAUCinf of Ritlecitinib: MR Capsules Under Fed vs Fasted Condition

AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

Time frame:
Pre-dose (0 hours), 1, 2, 3, 4, 6, 10, 12,16, 24, 36 and 48 hours post-dose on Day 1 of Period 1, 2, 3 (for fasted) or 4 (for fed)
Reported as:
Geometric mean · Nanogram*Hour per milliliter (ng*hr/ mL)
AUCinf of Ritlecitinib: MR Capsules Under Fed vs Fasted Condition
Nanogram*Hour per milliliter (ng*hr/ mL)Ritlecitinib 100 mg MR1 Capsule (Fasted)Ritlecitinib 100 mg MR2 Capsule (Fasted)Ritlecitinib 100 mg MR1 Capsule (Fed)Ritlecitinib 100 mg MR2 Capsule (Fed)
AUCinf of Ritlecitinib: MR Capsules Under Fed vs Fasted Condition1067 ± 28970.6 ± 221168 ± 201036 ± 15
Statistical analysis
  • Ritlecitinib 100 mg MR1 Capsule (Fasted) vs Ritlecitinib 100 mg MR1 Capsule (Fed) · Ratio of adjusted geometric means: 107.48 · 90% CI 96.46 to 119.76Ratios (Test/Reference) and 90% confidence intervals were expressed as percentages. Test = MR1 capsule (fed); Reference = MR1 capsule (fasted).
  • Ritlecitinib 100 mg MR2 Capsule (Fasted) vs Ritlecitinib 100 mg MR2 Capsule (Fed) · Ratio of adjusted geometric means: 109.63 · 90% CI 99.19 to 121.17Ratios (Test/Reference) and 90% confidence intervals were expressed as percentages. Test = MR2 capsule (fed); Reference = MR2 capsule (fasted).
SecondaryNumber of Participants With Adverse Events (AEs)

An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
From start of study treatment up to 35 days after administration of last dose of study intervention (maximum up to 45 days)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsRitlecitinib 100 mg Oral Solution (Fasted)Ritlecitinib 100 mg MR1 Capsule (Fasted)Ritlecitinib 100 mg MR2 Capsule (Fasted)Ritlecitinib 100 mg MR1 Capsule (Fed)Ritlecitinib 100 mg MR2 Capsule (Fed)
Number of Participants With Adverse Events (AEs)35301
SecondaryNumber of Participants With Clinically Significant Laboratory Test Abnormalities

Laboratory parameters included: Hematology: lymphocytes/leukocytes, eosinophils/leukocytes greater than (\>) 1.2\*upper limit of normal (ULN) (percent \[%\]), neutrophils/leukocytes less than (\<) 0.8\*lower limit of normal (LLN) (%); Urinalysis: urine hemoglobin, nitrite greater than or equal to (\>=) 1, bacteria \> 20 (per high power field \[/HPF\]). Clinical significance was judged by investigator.

Time frame:
From start of study treatment up to Day 3 of Period 4 (maximum up to Day 12, each Period = 3 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Laboratory Test Abnormalities
ParticipantsRitlecitinib 100 mg Oral Solution (Fasted)Ritlecitinib 100 mg MR1 Capsule (Fasted)Ritlecitinib 100 mg MR2 Capsule (Fasted)Ritlecitinib 100 mg MR1 Capsule (Fed)Ritlecitinib 100 mg (MR2 Capsule) Fed
Number of Participants With Clinically Significant Laboratory Test Abnormalities00000
SecondaryNumber of Participants With Clinically Significant Vital Signs Abnormalities

Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate (PR) were measured in a supine position. Criteria for vital signs included: SBP: value less than (\<) 90 millimeter of mercury (mmHg), change greater than or equal to (\>=) 30 mmHg decrease, change \>= 30 mmHg increase; DBP: value \< 50 mmHg, change \>= 20 mmHg decrease, change \>= 20 mmHg increase; PR: value \< 40 beats per minute (bpm), value \> 120 bpm. Clinical significance was judged by investigator.

Time frame:
From start of study treatment up to Day 3 of Period 4 (maximum up to Day 12, each Period = 3 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Vital Signs Abnormalities
ParticipantsRitlecitinib 100 mg Oral Solution (Fasted)Ritlecitinib 100 mg MR1 Capsule (Fasted)Ritlecitinib 100 mg MR2 Capsule (Fasted)Ritlecitinib 100 mg MR1 Capsule (Fed)Ritlecitinib 100 mg (MR2 Capsule) Fed
Number of Participants With Clinically Significant Vital Signs Abnormalities00000
SecondaryNumber of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities

Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT, corrected QT (Fridericia method) (QTcF) and QRS intervals. Clinical significance was judged by investigator.

Time frame:
From start of study treatment up to Day 3 of Period 4 (maximum up to Day 12, each Period = 3 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities
ParticipantsRitlecitinib 100 mg Oral Solution (Fasted)Ritlecitinib 100 mg MR1 Capsule (Fasted)Ritlecitinib 100 mg MR2 Capsule (Fasted)Ritlecitinib 100 mg MR1 Capsule (Fed)Ritlecitinib 100 mg MR2 Capsule (Fed)
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities10000

Adverse events

Collected over From start of study treatment up to 35 days after administration of last dose of study intervention (maximum up to 45 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ritlecitinib 100 mg Oral Solution (Fasted)0/12 (0%)0/12 (0%)3/12 (25%)
Ritlecitinib 100 mg MR1 Capsules (Fasted)0/11 (0%)0/11 (0%)5/11 (45.5%)
Ritlecitinib 100 mg MR2 Capsules (Fasted)0/12 (0%)0/12 (0%)3/12 (25%)
Ritlecitinib 100 mg MR1 Capsules (Fed)0/5 (0%)0/5 (0%)0/5 (0%)
Ritlecitinib 100 mg MR2 Capsules (Fed)0/6 (0%)0/6 (0%)1/6 (16.7%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventRitlecitinib 100 mg Oral Solution (Fasted)Ritlecitinib 100 mg MR1 Capsules (Fasted)Ritlecitinib 100 mg MR2 Capsules (Fasted)Ritlecitinib 100 mg MR1 Capsules (Fed)Ritlecitinib 100 mg MR2 Capsules (Fed)
HaematomaVascular disorders0/121/113/120/50/6
ErythemaSkin and subcutaneous tissue disorders0/120/110/120/51/6
Abdominal painGastrointestinal disorders0/121/110/120/50/6
ChillsGeneral disorders0/121/110/120/50/6
Pain in extremityMusculoskeletal and connective tissue disorders0/121/110/120/50/6
Night sweatsSkin and subcutaneous tissue disorders0/121/110/120/50/6
PruritusSkin and subcutaneous tissue disorders0/121/110/120/50/6
Atrioventricular block first degreeCardiac disorders1/120/110/120/50/6
DiarrhoeaGastrointestinal disorders0/120/111/120/50/6
Vessel puncture site painGeneral disorders1/120/110/120/50/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Treatment Sequence 1: A Then B Then C Then B (Fed)Treatment Sequence 2: B Then C Then A Then B (Fed)Treatment Sequence 3: C Then A Then B Then B (Fed)Treatment Sequence 4: A Then B Then C Then C (Fed)Treatment Sequence 5: B Then C Then A Then C (Fed)Treatment Sequence 6: C Then A Then B Then C (Fed)Total
<=18 years0000000
Between 18 and 65 years22121210
>=65 years0010102
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Sequence 1: A Then B Then C Then B (Fed)Treatment Sequence 2: B Then C Then A Then B (Fed)Treatment Sequence 3: C Then A Then B Then B (Fed)Treatment Sequence 4: A Then B Then C Then C (Fed)Treatment Sequence 5: B Then C Then A Then C (Fed)Treatment Sequence 6: C Then A Then B Then C (Fed)Total
Female0001001
Male22212211
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment Sequence 1: A Then B Then C Then B (Fed)Treatment Sequence 2: B Then C Then A Then B (Fed)Treatment Sequence 3: C Then A Then B Then B (Fed)Treatment Sequence 4: A Then B Then C Then C (Fed)Treatment Sequence 5: B Then C Then A Then C (Fed)Treatment Sequence 6: C Then A Then B Then C (Fed)Total
Hispanic or Latino0000011
Not Hispanic or Latino22122110
Unknown or Not Reported0010001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment Sequence 1: A Then B Then C Then B (Fed)Treatment Sequence 2: B Then C Then A Then B (Fed)Treatment Sequence 3: C Then A Then B Then B (Fed)Treatment Sequence 4: A Then B Then C Then C (Fed)Treatment Sequence 5: B Then C Then A Then C (Fed)Treatment Sequence 6: C Then A Then B Then C (Fed)Total
American Indian or Alaska Native0000000
Asian0000000
Native Hawaiian or Other Pacific Islander0000000
Black or African American0011114
White2211118
More than one race0000000
Unknown or Not Reported0000000
08

Study locations

1 site
  • Pfizer Clinical Research Unit - Brussels
    Brussels, Bruxelles-capitale, Région DE B-1070, Belgium
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in Mar 2024, 1 month.

Results were first posted in Apr 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2023
First posted
Dec 15, 2023
StartActual
Feb 1, 2024
Primary completionActual
Mar 28, 2024
CompletionActual
Mar 28, 2024
Results first posted
Apr 10, 2025
Last update
Apr 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06172348
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 15, 2023
Start date
Feb 1, 2024
Primary completion
Mar 28, 2024
Completion
Mar 28, 2024
Results posted
Apr 10, 2025
Last update
Apr 10, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-06651600

Start the discussion